Obesity Clinical Trial
— ExoABariOfficial title:
A Pilot Study " Effect of Acute Exercise on Food Intake and Energy Expenditure Following a Gastric Bypass: A Better Understanding of Weight Maintenance for Better Intervention"
This pilot study will use a crossover design to explore the effects of acute exercise following bariatric surgery on food intake, energy expenditure, appetite, food reward, appetite hormones, and inflammatory response. Participants will take part in a moderate-intensity exercise session and control condition of 50 minutes. The energy balance will be assessed for 3 days following the condition by giving the participants all the food they can consume for 3 days and having them wear an accelerometer. The investigators hypothesize that post-gastric bypass participants with higher weight regain will have a higher compensation in response to exercise, thus an increase in food intake and/or a decrease in total energy expenditure after exercise compared to participants with less weight regain; also post-gastric bypass participants with a higher weight regain will have a lower inflammatory response to exercise compared to the group with less weight regain.
| Status | Recruiting |
| Enrollment | 30 |
| Est. completion date | September 30, 2023 |
| Est. primary completion date | March 31, 2023 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - declare to be an adult (= 18 years old) - self-declared physically inactive (practicing less than 150 min/week of moderate to high intensity physical activity) - received a gastric bypass Roux-en-Y more than 24 months ago at the Ottawa Hospital - have regained weight =5%/year of total weight loss at nadir or =15%/year (n=15 regain) Exclusion Criteria: - be pregnant, breastfeeding or menopausal - have depressive symptoms (score =16 at the Center Epidemiologic Depression-Scale) - take medication that may influence appetite or weight loss - declare they cannot walk for 50 minutes - be classified as high risk according to the stratification model of the ACSM (people with heart disease, Peripheral vascular or cerebrovascular disease, chronic obstructive pulmonary disease, asthma, interstitial lung disease or cystic fibrosis, type 1 and 2 diabetes, thyroid disorders, kidney or liver disease) and not having medical authorization. |
| Country | Name | City | State |
|---|---|---|---|
| Canada | Aurelie Baillot | Gatineau | Quebec |
| Lead Sponsor | Collaborator |
|---|---|
| Universite du Quebec en Outaouais | Université de Montréal, Université de Sherbrooke, University of Ottawa |
Canada,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Change of energy intake between rest and exercise conditions (kcal/d) | The energy intake and macronutrients from the ad libitum will be measured with the validated technique of the food menu. A total of 62 items will be on the menu to ensure that sufficient hot meals, snacks, fruits, vegetables and beverages are available to the participants. Briefly, participants will be invited to choose from this validated menu, their breakfast, the meals they would like to have for lunch and after lunch the meals they would like to eat for the next 3 days (from midnight to midnight). The research assistant will instruct them to consume as much of these products as they want. All selected foods will be prepared and measured according to the guidelines described above. The food and beverages selected for the 3 days will be packed in plastic containers or bottles, which will be placed in a portable cooler for the participants to take with them. They must return all leftovers, packaging and peels in their original containers. | At least one week after baseline evaluation (visit 2) and 15 days to a maximum of 2 months after visit 2 | |
| Primary | Change of total energy expenditure post-experimentation between rest and exercise conditions (kcal/d) | Total energy expenditure: Using an accelerometer (Actigraph® GT3X+) worn on the right side at the waist for 3 days following the experimental conditions (except during showering and aquatic physical activities), total EE will be estimate (ActiLife® Software). In parallel, the participant will have to complete a physical activity logbook during the 3 days of wearing the accelerometer. | At least one week after baseline evaluation (visit 2) and 15 days to a maximum of 2 months after visit 2 | |
| Secondary | Change of appetite sensation score during experimentation and between conditions; visual analog scale (0-100mm) | Appetite and satiety will be measured using a computer-based visual analogue scale (VAS) (0-100mm) in the morning during fasting, before/after exercise, before/after ad libitum buffet as well as 1 and 2 hours after eating. The desire to eat, hunger, satiety and potential food consumption will be assessed using the following questions: 1) "How intense is your desire to eat?" (Very weak - very strong); 2) "How hungry are you?" Not at all hungry - as hungry as ever); 3) "How full are you feeling?" (Not at all - Completely), and 4) "How much food do you think you can eat?" (Nothing at all - A large quantity). Higher scores mean higher desire to eat, appettite, and a lower satiety. | At least one week after baseline evaluation (visit 2) and 15 days to a maximum of 2 months after visit 2 | |
| Secondary | Change of food rewards score during experimentation and between conditions, The Leeds Food Preference Questionnaire | The Leeds Food Preference Questionnaire (LFPQ) will be used before and 1 hour after the meal during the experimental conditions to assess food reward, i.e. explicit food pleasure and implicit and explicit food motivation. This questionnaire is a validated computerized procedure, during which 16 personalized different food images will be presented to participants for approximately 10 minutes. Food images were previously classified according to fat content (rich vs. low) and/or taste (salty vs. sweet) to form four categories: high fat and salt, low fat and salt, high fat and sugar, and low fat and sugar. | At least one week after baseline evaluation (visit 2) and 15 days to a maximum of 2 months after visit 2 | |
| Secondary | Change of blood IL-6 concentration during experimentation and between conditions | Blood samples taken with a catheter placed in the anterior ulnar vein of the dominant arm will be collected by a qualified nurse. The inflammatory profile (IL-6, IL-10, IL-1ra, IL-8, TNF-a, sTNFR, MIP-1ß, MCP-1) will be evaluated with X-Map technology using Luminex 200 (EMD Millipore, Burlington, MA, USA). Blood samples will be collected 5 times during each experimental visits: morning during fasting, before/after exercise or control condition, 30 minutes after exercise or control condition and before lunch. | At least one week after baseline evaluation (visit 2) and 15 days to a maximum of 2 months after visit 2 | |
| Secondary | Baseline resting energy expenditure (kcal/d) | Resting energy expenditure will be evaluated by indirect calorimetry with continuous evaluation of O2 and CO2 sampled with a transparent hood, after calibration of the gas analyzers. | Baseline | |
| Secondary | Exercise energy expenditure (kcal/d) | Exercise energy expenditure will be evaluated by indirect calorimetry with continuous evaluation of O2 and CO2 sampled with a mouthpiece, after calibration of the gas analyzers. | Baseline and during the exercise condition = at least one week after baseline evaluation (visit 2) OR 15 days to a maximum of 2 months after visit 2 | |
| Secondary | Change of blood ghrelin concentration during experimentation and between conditions (pg/ml) | Blood samples taken with a catheter placed in the anterior ulnar vein of the dominant arm will be collected by a qualified nurse. The blood plasma samples collected for ghrelin analysis will be collected in EDTA tubes. Immediately after blood sampling, a precise protocol will be used to preserve their integrity. The analysis of ghrelin will be carried out with ELISA kits specific to ghrelin: Millipore, Etobicoke, ON, Canada. Blood samples will be collected 5 times during the experimental visits: morning during fasting, before/after exercise or control condition, 30 minutes after exercise or control condition and before lunch. | At least one week after baseline evaluation (visit 2) and 15 days to a maximum of 2 months after visit 2 | |
| Secondary | Change of blood Glucagon-like peptide-1 (GLP-1) concentration during experimentation and between conditions (pg/ml) | Blood samples taken with a catheter placed in the anterior ulnar vein of the dominant arm will be collected by a qualified nurse. The blood plasma samples collected for GLP-1 analysis will be collected in EDTA tubes. Immediately after blood sampling, a precise protocol will be used to preserve their integrity. The analysis of GLP-1 will be carried out with ELISA kits specific to ghrelin: Linco Research, St Louis, MO, USA. Blood samples will be collected 5 times during the experimental visits: morning during fasting, before/after exercise or control condition, 30 minutes after exercise or control condition and before lunch. | At least one week after baseline evaluation (visit 2) and 15 days to a maximum of 2 months after visit 2 | |
| Secondary | Change of blood peptide YY (PYY) concentration during experimentation and between conditions (pg/ml) | Blood samples taken with a catheter placed in the anterior ulnar vein of the dominant arm will be collected by a qualified nurse. The blood plasma samples collected for PYY analysis will be collected in EDTA tubes. Immediately after blood sampling, a precise protocol will be used to preserve their integrity. The analysis of PYY will be carried out with ELISA kits specific to PYY: Linco Research, St Louis, MO, USA. Blood samples will be collected 5 times during the experimental visits: morning during fasting, before/after exercise or control condition, 30 minutes after exercise or control condition and before lunch. | At least one week after baseline evaluation (visit 2) and 15 days to a maximum of 2 months after visit 2 | |
| Secondary | Baseline Kg of fat free mass; Dual Energy X-ray Absorptiometry | It will be evaluated by Dual Energy X-ray Absorptiometry. | Baseline | |
| Secondary | Baseline Eating behavior score; The Three Factor Eating Questionnaire | The Three Factor Eating Questionnaire, also called Eating Inventory, developed by Stunkard et Messick will be used to identify different eating behaviours or motivations to eat. This 51-question, self-administered questionnaire identifies three "factors": cognitive restraint (21 questions) which measures dietary self-regulation; disinhibition (16 questions) which assesses loss of control over eating and susceptibility to hunger (14 questions), which describes subjective feelings of hunger and cravings.All TFEQ items are coded with either 0 or 1 point leading to maximum sum scores of 21 points for the domain of 'cognitive restraint', 16 points for 'disinhibition' and 14 points for 'hunger'. Higher scores indicate stronger characteristic values in the domains. | Baseline | |
| Secondary | Presence of binge eating behaviors; Eating Disorder Examination Questionnaire and Binge Eating Scale | The first section of the Eating Disorder Examination Questionnaire consists of 22 items that allow participants to record the frequency and intensity with which they adopted inappropriate attitudes and behaviours over the past four weeks. A score greater than or equal to 4 is considered clinically significant and suggests a diagnosis of an eating disorder.
The Binge Eating Scale is a validated 16-item self-administered questionnaire. For each item, the participant must choose from several sentences the wording that best corresponds to their current situation. The score can vary between 0 and 3 or between 0 and 2 for each item. A total score (obtained from the sum of the scores of each of the 16 items) greater than or equal to 18 indicates significant binge eating behaviors. |
Baseline | |
| Secondary | Baseline Kg of fat mass | It will be evaluated by Dual Energy X-ray Absorptiometry. | Baseline | |
| Secondary | Baseline total energy expenditure | Using an accelerometer (Actigraph® GT3X+) worn on the right side at the waist for 7 days after the preliminary visit (except during showering and aquatic physical activities), total EE will be estimate (ActiLife® Software). In parallel, the participant will have to complete a physical activity logbook during the 7 days of wearing the accelerometer. | Baseline | |
| Secondary | Change of blood IL-10 concentration during experimentation and between conditions (pg/ml) | Blood samples taken with a catheter placed in the anterior ulnar vein of the dominant arm will be collected by a qualified nurse. The inflammatory profile (IL-6, IL-10, IL-1ra, IL-8, TNF-a, sTNFR, MIP-1ß, MCP-1) will be evaluated with X-Map technology using Luminex 200 (EMD Millipore, Burlington, MA, USA). Blood samples will be collected 5 times during each experimental visits: morning during fasting, before/after exercise or control condition, 30 minutes after exercise or control condition and before lunch. | At least one week after baseline evaluation (visit 2) and 15 days to a maximum of 2 months after visit 2 | |
| Secondary | Change of blood IL-1ra concentration during experimentation and between conditions (pg/ml) | Blood samples taken with a catheter placed in the anterior ulnar vein of the dominant arm will be collected by a qualified nurse. The inflammatory profile (IL-6, IL-10, IL-1ra, IL-8, TNF-a, sTNFR, MIP-1ß, MCP-1) will be evaluated with X-Map technology using Luminex 200 (EMD Millipore, Burlington, MA, USA). Blood samples will be collected 5 times during each experimental visits: morning during fasting, before/after exercise or control condition, 30 minutes after exercise or control condition and before lunch. | At least one week after baseline evaluation (visit 2) and 15 days to a maximum of 2 months after visit 2 | |
| Secondary | Change of blood IL-8 concentration during experimentation and between conditions (pg/ml) | Blood samples taken with a catheter placed in the anterior ulnar vein of the dominant arm will be collected by a qualified nurse. The inflammatory profile (IL-6, IL-10, IL-1ra, IL-8, TNF-a, sTNFR, MIP-1ß, MCP-1) will be evaluated with X-Map technology using Luminex 200 (EMD Millipore, Burlington, MA, USA). Blood samples will be collected 5 times during each experimental visits: morning during fasting, before/after exercise or control condition, 30 minutes after exercise or control condition and before lunch. | At least one week after baseline evaluation (visit 2) and 15 days to a maximum of 2 months after visit 2 | |
| Secondary | Change of blood TNF-a concentration during experimentation and between conditions (pg/ml) | Blood samples taken with a catheter placed in the anterior ulnar vein of the dominant arm will be collected by a qualified nurse. The inflammatory profile (IL-6, IL-10, IL-1ra, IL-8, TNF-a, sTNFR, MIP-1ß, MCP-1) will be evaluated with X-Map technology using Luminex 200 (EMD Millipore, Burlington, MA, USA). Blood samples will be collected 5 times during each experimental visits: morning during fasting, before/after exercise or control condition, 30 minutes after exercise or control condition and before lunch. | At least one week after baseline evaluation (visit 2) and 15 days to a maximum of 2 months after visit 2 | |
| Secondary | Change of blood sTNFR concentration during experimentation and between conditions (pg/ml) | Blood samples taken with a catheter placed in the anterior ulnar vein of the dominant arm will be collected by a qualified nurse. The inflammatory profile (IL-6, IL-10, IL-1ra, IL-8, TNF-a, sTNFR, MIP-1ß, MCP-1) will be evaluated with X-Map technology using Luminex 200 (EMD Millipore, Burlington, MA, USA). Blood samples will be collected 5 times during each experimental visits: morning during fasting, before/after exercise or control condition, 30 minutes after exercise or control condition and before lunch. | At least one week after baseline evaluation (visit 2) and 15 days to a maximum of 2 months after visit 2 | |
| Secondary | Change of blood MIP-1ß concentration during experimentation and between conditions (pg/ml) | Blood samples taken with a catheter placed in the anterior ulnar vein of the dominant arm will be collected by a qualified nurse. The inflammatory profile (IL-6, IL-10, IL-1ra, IL-8, TNF-a, sTNFR, MIP-1ß, MCP-1) will be evaluated with X-Map technology using Luminex 200 (EMD Millipore, Burlington, MA, USA). Blood samples will be collected 5 times during each experimental visits: morning during fasting, before/after exercise or control condition, 30 minutes after exercise or control condition and before lunch. | At least one week after baseline evaluation (visit 2) and 15 days to a maximum of 2 months after visit 2 | |
| Secondary | Change of blood MCP-1 concentration during experimentation and between conditions (pg/ml) | Blood samples taken with a catheter placed in the anterior ulnar vein of the dominant arm will be collected by a qualified nurse. The inflammatory profile (IL-6, IL-10, IL-1ra, IL-8, TNF-a, sTNFR, MIP-1ß, MCP-1) will be evaluated with X-Map technology using Luminex 200 (EMD Millipore, Burlington, MA, USA). Blood samples will be collected 5 times during each experimental visits: morning during fasting, before/after exercise or control condition, 30 minutes after exercise or control condition and before lunch. | At least one week after baseline evaluation (visit 2) and 15 days to a maximum of 2 months after visit 2 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
| Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
| Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
| Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
| Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
| Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
| Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
| Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
| Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
| Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
| Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
| Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
| Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
| Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
| Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
| Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
| Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |